thalidomide has been researched along with Febrile Neutropenia in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Febrile Neutropenia: Fever accompanied by a significant reduction in the number of NEUTROPHILS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment benefit in multiple myeloma (MM) patients with high-risk cytogenetics remains suboptimal." | 1.62 | Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. ( Alegre, A; Campana, F; Delimpasi, S; Facon, T; Harrison, SJ; Hulin, C; Inchauspé, M; Macé, S; Perrot, A; Richardson, P; Risse, ML; Simpson, D; Spencer, A; Sunami, K; van de Velde, H; Vlummens, P; Wang, MC; Yong, K, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meunier, M | 1 |
| Larabi, A | 1 |
| Schacherer, M | 1 |
| Deteix, C | 1 |
| Courby, S | 1 |
| Cahn, JY | 1 |
| Lee, HS | 1 |
| Kim, K | 1 |
| Kim, SJ | 1 |
| Lee, JJ | 1 |
| Kim, I | 1 |
| Kim, JS | 1 |
| Eom, HS | 1 |
| Yoon, DH | 1 |
| Suh, C | 1 |
| Shin, HJ | 1 |
| Mun, YC | 1 |
| Kim, MK | 1 |
| Lim, SN | 1 |
| Choi, CW | 1 |
| Kang, HJ | 1 |
| Yoon, SS | 1 |
| Min, CK | 1 |
| Harrison, SJ | 1 |
| Perrot, A | 1 |
| Alegre, A | 1 |
| Simpson, D | 1 |
| Wang, MC | 1 |
| Spencer, A | 1 |
| Delimpasi, S | 1 |
| Hulin, C | 1 |
| Sunami, K | 1 |
| Facon, T | 1 |
| Vlummens, P | 1 |
| Yong, K | 1 |
| Campana, F | 1 |
| Inchauspé, M | 1 |
| Macé, S | 1 |
| Risse, ML | 1 |
| van de Velde, H | 1 |
| Richardson, P | 1 |
1 trial available for thalidomide and Febrile Neutropenia
| Article | Year |
|---|---|
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2020 |
2 other studies available for thalidomide and Febrile Neutropenia
| Article | Year |
|---|---|
Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Substitution; | 2020 |
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplasti | 2021 |